Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice

Sponsor
AstraZeneca
Study ID
NCT05250011
Status
Completed

Conditions

  • Heart Failure, Reduced Ejection Fraction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.

Study Details

This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with dapagliflozin according to the approved HFrEF indication. The study is aimed at providing insights into real-world drug utilization and treatment patterns of dapagliflozin in the Italian HFrEF setting, as well as patient-reported outcomes including quality of life.

Key Dates

Start date
Apr 19, 2022
Status verified
Mar 2025
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024

Study Design

Enrollment
252 participants (actual)

Arms

  • Arm: Single-cohort
    Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice

Primary Outcome Measure

Baseline characteristics of participants [ Time Frame: Baseline (enrollment) ]

Related Studies